



ACOBIOM, partner of Toulouse Hospital and the BACAP program, a clinical & biological database dedicated to pancreatic cancer

Montpellier, France, May 16, 2018 - Acobiom, a company specialized in the discovery of biological markers and in the development of innovative Diagnostics in Precision Medicine, announces today the signature of a partnership with Toulouse Hospital and the BACAP program.

The BACAP clinical & biological program, coordinated by Pr Barbara BOURNET and Dr Cindy CANIVET from Toulouse Hospital, aims to collect in one database: clinical and epidemiological data, as well as associated biological samples, collected from pancreatic cancer patients. These patients suffering from pancreatic cancer will be enrolled by the 15 clinical centers*, partners of the BACAP program.

Granted by INCa and validated by the different French regulatory authorities (CCTIRS, CNIL, CPP, collection authorization obtained from French Health ministry), the BACAP program enrolls the patients (more than 1000 so far) that gave their informed consent.

As this BACAP database and these biological samples (collected before any treatment) is available for the scientific community since May 2015, ACOBIOM obtained the authorization to have access to this database to develop and validate its predictive diagnostics of therapeutic response in pancreatic cancer treatment (GemciTest in a first step).

The partnership between Toulouse Hospital and ACOBIOM has been signed for the 2018 and 2019 years.

For more information about the BACAP clinical & biological database: www.chu-toulouse.fr/-projet-bacap

For more information about GemciTest:

www.acobiom.com/wp-content/uploads/2016/12/acobiom_gemcitest-sum-up_20180410.pdf

* the 15 clinical centres, partners of BACAP: Toulouse (Toulouse Hospital), Montpellier (Cancer Regional Institute of Montpellier & Montpellier Hospital), Marseille (Public Hospitals of Marseille Organisation – North Hospital Nord & the Timone Hospital), Nice (Nice Hospital – Archet Hospital), Lyon (Léon Bérard Centre & Jean Mermoz private Hospital), Paris (Public Hospitals of Paris Organisation - Saint-Louis Hospital), Paris (Trocadéro Clinic), Lille (Lille Hospital), Bordeaux (Bordeaux Hospital), Pau (Pau Hospital).

About ACOBIOM: www.acobiom.com

Acobiom is a biotechnology company specialized in the discovery of new biological markers and the development of innovative diagnostics focused on Precision Medicine or Personalized Medicine. Precision medicine is meeting patients' needs: adapting treatments to patient biological profiles, reducing drug side effects, better managing health expenditures and offering better therapeutic efficacy. Biological markers are identified and selected by Acobiom using its proprietary technological platform, which combines genomics, transcriptomics, bioinformatics, and data science. With its unique scientific expertise in analyzing gene expression in blood cells and whole blood, Acobiom has established its position in the field of Precision Medicine and in the development of diagnostics in order to select the best-in-class treatment. This approach enables targeted drug selection that matches the patient's own phenotypic profile for the treatment of diseases. Founded in 1999, Acobiom is located in the Biopole Euromedecine life sciences business center in Montpellier, France, and is a member of local health care clusters.

ACOBIOM

1682, rue de la Valsière - CS77394 - Cap Delta - Biopole Euromedecine II - 34184 Montpellier Cedex 4 - France
Tel.: +33 (0)467 419 748 - Fax : +33 (0)467 457 726 - Email : info@acobiom.com - Web : www.acobiom.com